Group 1 - The core viewpoint of the article is that Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Pharmaceutical Biotechnology (Beijing) Co., Ltd. to promote the application of artificial intelligence (AI) in the research and development of medical beauty products [1] - The collaboration aims to establish an AI research and development company led by Four Seasons Pharmaceutical, focusing on the exploration of AI-driven new medical beauty product development [1] - This initiative marks a significant step in the strategic layout of the "AI + Medical Beauty" innovation track for the company [1]

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" landscape [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven innovations in medical aesthetics [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will provide its proprietary protein design automation platform and core technologies [1] Group 2: Strategic Objectives - The collaboration aims to break through raw material bottlenecks and upgrade the medical aesthetics business by utilizing Deep Origin's unique protein design platform to address challenges in the design, optimization, and expression of core injectable materials [1] - The initiative is expected to reduce reliance on imported high-end materials, promoting the upgrade of medical aesthetics products towards "high-end and domestically produced" solutions, thereby strengthening market share and brand influence [1] Group 3: R&D Efficiency and Innovation - The partnership will enhance the efficiency of medical aesthetics R&D processes by integrating deep generative models and high-throughput experimental validation systems, which will shorten the early-stage molecular screening cycle and lower development costs [2] - The establishment of the AI R&D company will focus on creating globally innovative raw materials and products, addressing unmet market needs and injecting momentum into the long-term development of the medical aesthetics business [2]

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" landscape [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven innovations in medical aesthetics [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will contribute its proprietary protein design automation platform and core technologies [1] Group 2: Strategic Objectives - The collaboration aims to break through raw material bottlenecks and upgrade the medical aesthetics business by utilizing Deep Origin's unique protein design platform to address challenges in the design, optimization, and expression of core injectable materials [1] - The initiative is expected to reduce reliance on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetics products towards "high-end and domestically produced" offerings, thereby strengthening market share and brand influence [1] Group 3: R&D Efficiency and Innovation - The partnership will enhance the efficiency of medical aesthetics R&D processes by integrating deep generative models and high-throughput experimental validation systems, which will shorten the early-stage molecular screening cycle and reduce development costs [2] - The establishment of the AI R&D company will focus on globally pioneering raw materials and product development, addressing unmet market needs and injecting momentum into the long-term growth of Four Seasons' medical aesthetics business [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 四環醫藥與深原質藥聯合成立AI研發公司 探索開發AI驅動的新型醫美產品 四 環 醫 藥 控 股 集 團 有 限 公 司（「本公司」或「四環醫藥」，連 同 其 附 屬 公 司，統 稱 為「本集團」）董 事 會（「董事會」）欣 然 宣 佈，為 推 動 人 工 智 慧 技 術（「AI」）在 醫 療 美 容（「醫 美」）產 品 研 發 領 域 的 深 度 應 用 與 產 業 化 落 地，本 集 團 已 與 深 原 質 藥 生 物 科 技（北 京）有 限 公 司（「深原質藥」）簽 署 框 架 協 議。雙 方 將 聯 合 成 立 由 本 集 團 主 導 的AI研 發 公 司，共 同 探 ...